Floatz logo

3-(.ALPHA.-ACETONYL-P-NITROBENZYL)-4-HYDROXYCOUMARIN

Atrial Fibrillation

University of EdinburghSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Atrial Fibrillation cohort.

Asset / SponsorPhaseRating
Edoxaban
National Taiwan University Hospital
Phase 4A
Dabigatran
Pfizer
Phase 4BBB
Rivaroxaban
VA Office of Research and Development
Phase 4BBB
Apixaban
Regeneron Pharmaceuticals
Phase 4BBB
WARFARIN
Pfizer
Phase 4BBB

View all 40 →

Same molecule, other indications

3-(.ALPHA.-ACETONYL-P-NITROBENZYL)-4-HYDROXYCOUMARIN is also rated in:

stroke disorderDormant
BB
Indicative · Phase 4
65 / 100
View asset →
subarachnoid hemorrhageDormant
BB
Indicative · Phase 3
64 / 100
View asset →
intracerebral hemorrhageDormant
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →